Combined Hormonal Contraceptive Use and Risk of Breast Cancer in a Population of Women With a Family History

  title={Combined Hormonal Contraceptive Use and Risk of Breast Cancer in a Population of Women With a Family History},
  author={G. Grandi and A. Toss and A. Cagnacci and L. Marcheselli and Silvia Pavesi and F. Facchinetti and S. Cascinu and L. Cortesi},
  journal={Clinical Breast Cancer},
Micro‐Abstract CHCs are the most used methods of contraception in the more developed world. Their use does not increase the risk of breast cancer in women with a family history of BC from our Family Cancer Clinic. These results are confirmed for very‐high‐risk (BRCA1‐2), high‐risk and intermediate‐risk groups. Background: We estimated the association between combined hormonal contraceptive (CHC) use and breast cancer (BC) incidence in a well‐selected population of women at familial risk of BC… Expand
Prescribing Oral Contraceptives in Women With Breast Diseases : A Matter of Concern for the Gynecologist Breast
Results: Oral contraceptives are contraindicated in women with current or previous breast cancer. Among women at high risk for breast cancer, those with preceding chest wall irradiation should notExpand
Health outcomes associated with use of hormonal contraception: breast cancer
Overall, breast cancer risk is low among hormonal contraceptive users and women should be counseled accordingly. Expand
Breast cancer risk of hormonal contraception: Counselling considering new evidence.
Evidence is provided that may help gynaecologists and oncologists in discussing with their patients the use of HC, and patients must be informed that notwithstanding the slightly increased breast cancer risk, the overall cancer risk may still be lower than non-users. Expand
Hormonal contraceptives and breast cancer: Clinical data.
It is of interest that long-term follow up data on women who enrolled in the initial cohorts, like that of the Royal College of General Practitioners', have shown a considerable protection against cancer of the ovary, endometrium, or colorectum. Expand
Attitudes of women towards products containing hormones (hormonal contraceptives or hormone therapy): what changes from pre to postmenopause?
The data suggest that patients are primarily concerned about the effects of hormonal treatments on venous thrombosis, mood, breast cancer and cervical cancer risk, and, later in life, about their impact on weight gain, breast and ovarian cancer risk. Expand
Oral contraception use in BRCA gene mutation carriers: information for counselling in routine clinical practice
Department of Obstetrics and Gynecology, IRCCS San Matteo Foundation, 27100 Pavia, Italy Department of Medical Oncology, IRCCS San Matteo Foundation, 27100 Pavia, Italy General Surgery III, BreastExpand
Combined hormonal contraceptives in BRCA gene mutation carriers: why not?
The BRCA1/BRCA2 tumour suppressor genes, respectively, located in chromosome 17q and 13q, and diabetic pathways, are under investigation for their role in breast and ovarian cancers. Expand
A framework for personalized mammogram screening
It was found that older patients, those who were married, are more likely to get screened and those who had their first pregnancy at an older age are at higher risk of having an abnormal mammogram. Expand
Female Reproductive Dysfunction
Human reproduction depends on an intact hypothalamic-pituitary-gonadal axis. Hypothalamic gonadotropin-releasing hormone (GnRH) has been recognized as the central regulator of the production andExpand
Analytical Method Validation of RP-HPLC Method for Simultaneous Estimation of Levonorgestrel and Ethinylestradiol from Combined DrugProduct
The aim of recent study is to explore a rapid, sensitive and selective Reversed Phase HPLC method for simultaneous quantification of steroidal hormones Levonorgestrel and Ethinylestradiol from drugExpand


Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer.
The results suggest that women who have ever used earlier formulations of OCs and who also have a first-degree relative with breast cancer may be at particularly high risk for breast cancer. Expand
Oral Contraceptive Use and Risk of Breast Cancer among Women with a Family History of Breast Cancer: a Prospective Cohort Study
The data raise the possibility that relatively long duration of oral contraceptive use may be inversely associated with risk among women with a family history of breast cancer. Expand
Hormonal contraception and risk of cancer.
Protective effect of OC can be used as chemoprevention in young women who are BRCA mutation carriers and can be reassured that their decision to use combined OC is unlikely to place them at higher risk of developing cancer. Expand
Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group.
  • R. Brohet, D. Goldgar, +16 authors M. Rookus
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2007
No evidence was found among BRCA1/2 mutation carriers that current use of oral contraceptives is associated with risk of breast cancer more strongly than is past use, as is found in the general population, however, duration of use, especially before first full-term pregnancy, may be associated with an increasing risk of cancer. Expand
Use of oral contraceptives and breast cancer risk: The Norwegian-Swedish Women's Lifestyle and Health Cohort Study.
Current/recent use of OCs is associated with an increased breast cancer risk, and use of combined OCs and progestin-only pills seem to increase the risk at the same level. Expand
Oral contraceptives and the risk of breast cancer
There now is strong evidence that former OC use does not increase the breast cancer risk in later life when the disease is more prevalent, and current or previous use of oral contraception by women 35 to 64 years of age did not significantly increase the risk of breast cancer in this study. Expand
Risk of Breast Cancer by Type of Menopausal Hormone Therapy: a Case-Control Study among Post-Menopausal Women in France
Differential effects on breast cancer risk of progestagens and regimens specifically used in France confirmed that early users of MHT after onset of menopause were at greater risk than users who delayed treatment. Expand
Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies
The relation observed between breast cancer risk and hormone exposure is unusual, and it is not possible to infer from these data whether it is due to an earlier diagnosis of breast cancer in ever-users, the biological effects of hormonal contraceptives, or a combination of reasons. Expand
Breast cancer screening in women at increased risk according to different family histories: an update of the Modena Study Group experience
The rate of cancers detected in women at high risk according to BRCA status or strong family history, as defined according to the operational criteria, was significantly higher than expected in an age-matched general population. Expand
A prospective study of oral contraceptive use and risk of breast cancer (Nurses' Health Study, United States)
This study provides considerable evidence that long-term past OC use, either overall or prior to a first full-term pregnancy, does not result in any appreciable increase in breast cancer risk in women over 40 years of age. Expand